Chrome Holding Co.: M&A transaction — 23andMe completes $305M asset sale to TTAM Research Institute in bankruptcy

Chrome Holding Co.

Purchase price of $305M cash plus assumption of liabilities; Lemonaid Health excluded business acquired for $2.5M.
Buyer TTAM is an affiliate of co-founder Anne Wojcicki; transaction consummated July 14, 2025.
DIP credit facility with JMB Capital Partners fully repaid and terminated upon closing.
Chapter 11 cases remain pending; distribution of proceeds to shareholders to be disclosed later.
23andMe continues operating as part of TTAM, offering DNA testing and research services.

item 1.02 item 2.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Chrome Holding Co. completed a disposition involving TTAM Research Institute (closed 2025-07-14).

Action: disposition
Counterparty: TTAM Research Institute
Closing: 2025-07-14

Exact text from the filing

TTAM Research Institute (“TTAM”), a nonprofit public benefit corporation based in California and founded and led by Anne Wojcicki, today announced that it has completed the acquisition of the Personal Genome Service (PGS) and Research Services business lines of 23andMe Holding Co.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-25-158551

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.